RVL Pharmaceuticals PLC RVLP

Market cap
$14.1M
P/E
0.0×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
1.39 1.39 1.33 1.53 3.41 4.99 2.08
P/FCF ratio
13.31 13.31 10.50 12.36 17.86 0.00 0.00
P/Operating CF
48.33 48.33 11.55 542.29 (31.29) (3.58) (6.28)
P/B ratio
0.84 0.84 0.91 3.19 2.75 1.14 2.02
Price to Tangible BV
0.00 0.00 0.00 0.00 88.45 0.00 0.00
EV/Sales
2.52 2.52 2.08 2.25 4.82 5.32 2.33
EV/EBITDA
10.88 10.88 6.29 9.00 13.23 0.00 0.00
EV/Operating CF
21.84 21.84 14.61 16.10 20.76 (1.70) (3.06)
EV/FCF
24.13 24.13 16.42 18.24 25.26 (1.65) (3.00)
Quick Ratio
0.55 0.58 1.12 1.84 2.10 2.12 2.41
Current Ratio
0.80 0.92 1.51 2.27 3.10 2.95 2.89
Net Debt/EBITDA
23.78 4.24 2.27 2.90 27.89 (0.09) (0.29)
Debt/Assets
33.61% 34.86% 33.77% 58.32% 59.51% 31.94% 44.32%
Debt/Equity
0.71 0.74 0.70 2.36 2.35 0.60 1.11
Asset Turnover
0.23 0.26 0.31 0.38 0.07 0.07 0.36
Operating CF/Net income
1.07 (1.41) (0.34) (0.12) (0.22) 0.84 0.73
Capex/Depreciation
(0.35) (0.06) (0.02) (0.01) (0.03) (0.10) (0.04)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(9.28%) (9.13%) (26.76%) (108.67%) (76.32%) (76.11%) (80.88%)
ROA
(4.41%) (4.33%) (12.79%) (43.04%) (19.08%) (25.18%) (37.84%)
ROIC
(2.59%) (4.51%) (10.59%) (60.70%) (28.25%) (62.69%) (58.06%)
Return on Tangible Assets
(1,018.09%) (190.82%) (122.38%) (213.42%) (66.46%) (161.75%) (134.17%)
Average Days of Receivables
75.72 55.90 78.10 66.78 41.40 44.49 22.25
Research and Development Expense of Revenue
13.30% 17.37% 16.57% 13.46% 48.22% 39.60% 7.98%
Selling, General and Administrative Expense of Revenue
30.19% 23.18% 28.15% 38.76% 262.32% 499.76% 164.88%
Intangible Assets out of Total Assets
0.87 0.84 0.74 0.55 0.25 0.57 0.54
Share Based Compensation of Revenue
0.00% 0.00% 0.75% 2.05% 17.74% 43.39% 8.19%
Graham Net Nets
(0.83) (0.83) (0.68) (0.48) (0.40) (0.10) (0.20)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(61.23%) (61.23%) (64.39%) (73.68%) (31.31%) (87.96%) (48.70%)
Free Cash Flow Yield
7.51% 7.51% 9.53% 8.09% 5.60% (64.70%) (37.34%)
Revenue per Share
218.46 5.73 5.82 4.58 0.46 0.26 0.55
Operating CF per Share
(44.79) 1.35 0.83 0.64 0.29 (0.81) (0.42)
Capex per Share
(15.93) (0.16) (0.09) (0.08) (0.05) (0.03) (0.01)
Free Cash Flow per Share
(60.72) 1.19 0.74 0.57 0.24 (0.84) (0.43)
Cash per Share
19.56 0.81 1.56 1.83 1.88 0.60 0.50
Shareholders Equity per Share
465.21 10.17 8.48 2.19 1.55 1.14 0.57
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
465.21 10.17 8.48 2.19 1.55 1.14 0.57
Free Cash Flow
(60.72) 50.94 33.42 29.62 14.46 (56.51) (38.56)
Working Capital
(23.62) (9.85) 58.36 96.69 117.37 39.27 37.25
Capital Expenditures
(15.93) (6.90) (4.13) (3.95) (3.13) (1.78) (0.75)
Net Current Asset Value
(419.09) (369.13) (239.41) (175.92) (103.94) (8.56) (20.44)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.07 0.03 0.02 0.02 0.11 0.10 0.02
Net Profit Margin
(19.14%) (16.74%) (41.59%) (112.86%) (286.68%) (370.95%) (103.96%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.62 3.80 5.94 11.27 39.51 20.39 13.13
Cash ROIC
(8.91%) 3.34% 0.87% 0.69% 3.55% (34.03%) (25.62%)
Accounts Receivable Turnover
5.27 5.92 5.61 4.78 1.18 6.63 19.26
Accounts Payable Turnover
3.54 3.52 4.60 6.69 0.57 1.05 3.06
Inventory Turnover
6.83 6.81 6.78 4.89 0.28 2.71 11.66
Average Days of Payables
101.64 105.17 64.80 27.78 346.71 381.04 92.91
Days of Inventory on Hand
57.65 49.41 63.53 69.66 202.95 84.54 30.26
Average Receivables
41.48 41.48 47.03 50.17 23.53 2.64 2.58
Average Payables
35.52 35.52 30.47 16.68 5.81 3.45 3.09
Average Inventory
18.39 18.39 20.66 22.84 11.57 1.33 0.81
Average Assets
949.12 949.12 857.68 629.44 417.10 257.81 136.59
Average Common Equity
450.49 450.49 409.82 249.28 104.28 85.29 63.91

Fold the line items

Columns are period end dates